Peptide IntelNewsletter
← All updates
ScienceApril 22, 2026

Retatrutide — what the trial data does (and doesn't) tell us

A new generation of "Triple G" peptides is producing numbers that have left the scientific community stunned. Here's what to actually take from the data.

We are currently witnessing the birth of the "Triple G" era—a new generation of peptides that aim to do for metabolic health what the smartphone did for communication.

Retatrutide is the latest molecule from Eli Lilly to capture the world's attention. While semaglutide (Ozempic/Wegovy) targets one hormone and tirzepatide (Mounjaro/Zepbound) targets two, retatrutide targets three: GLP-1, GIP, and the glucagon receptor. This "triple agonist" approach has produced numbers in Phase 2 trials that have left the scientific community stunned. But as we look toward the 2026 Phase 3 readouts, it is important to separate the excitement from the evidence.

The power of three: how it differs

To understand why retatrutide is different, we have to look at its biological mechanism.

  • GLP-1 and GIP handle the "fullness" and insulin response we are already familiar with.
  • Glucagon is the new addition. Traditionally, we thought of glucagon as the hormone that raises blood sugar. However, research has investigated how activating the glucagon receptor can actually increase the body's energy expenditure (calorie burning) and improve liver fat metabolism.

In simple terms: if older peptides were about eating less, retatrutide is about eating less and burning more efficiently.

Reading the Phase 2 results

The Phase 2 data, published in The New England Journal of Medicine, was historic. Over 48 weeks, participants on the highest dose of retatrutide lost an average of 24.2% of their body weight. To put that in perspective: semaglutide typically shows around 15% weight loss over 68 weeks, and tirzepatide shows around 21–22% over 72 weeks. Retatrutide achieved more weight loss in less time. Furthermore, 100% of the participants in the high-dose group lost at least 5% of their body weight—a level of "responsiveness" that is almost unheard of in clinical pharmacology.

The side-effect caveats

Higher potency often comes with higher sensitivity. In the Phase 2 trials, researchers noted that while gastrointestinal side effects (nausea, vomiting) were similar to other GLP-1s, there was a unique observation: a dose-dependent increase in heart rate that peaked around 24 weeks.

While this heart rate increase eventually leveled off, it is a key area of focus for the ongoing Phase 3 trials. We don't yet know if this has long-term implications for cardiovascular health, or if it is simply a byproduct of the glucagon activation. Users in research circles have also reported more significant chills or skin sensitivity, though these reports remain secondary to the primary GI concerns.

What the data doesn't tell us yet

It is tempting to look at Phase 2 as a finished story, but we are still missing critical chapters. We do not yet have long-term cardiovascular outcomes data—the kind of study that tells us if the drug actually prevents heart attacks. We also don't know much about the maintenance phase. Is the weight loss sustainable after two or three years? Does the triple action lead to more muscle loss (sarcopenia) compared to dual-action peptides? These are the questions the Phase 3 TRIUMPH trials are designed to answer.

What to watch for through late 2026

The Phase 3 readouts expected in late 2025 and throughout 2026 will be the final hurdle. These trials involve thousands of participants compared to the hundreds in Phase 2 and will give us a much clearer picture of the safety profile. Specifically, we should look for data on liver health—retatrutide showed massive promise in reducing liver fat, which could make it a first-in-class treatment for metabolic-associated steatotic liver disease (MASLD).

Sources